Dr. Jones on the Safety of Venetoclax in CLL

Jeffrey Jones, MD, MPH
Published: Wednesday, Feb 22, 2017



Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).

One concern that has arisen as venetoclax has moved into the clinic is its toxicity profile, explains Jones. In earlier studies of venetoclax, there were cases of hyperacute tumor lysis syndrome that required urgent intervention in order to manage it.

In this phase II study, modifications were made, which led to a result of only 2 cases of biochemical tumor lysis reported between both groups of patients.
 


Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).

One concern that has arisen as venetoclax has moved into the clinic is its toxicity profile, explains Jones. In earlier studies of venetoclax, there were cases of hyperacute tumor lysis syndrome that required urgent intervention in order to manage it.

In this phase II study, modifications were made, which led to a result of only 2 cases of biochemical tumor lysis reported between both groups of patients.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x